We continuously promote the improvement of a comprehensive quality management system throughout the entire product lifecycle to ensure compliance with cGMP standards and regulatory developments in China, the United States, and Europe. The Company prioritizes quality, strengthens the segmented contract manufacturing management system for biological products, and achieves collaborative operations across multiple production sites and enterprises by dividing the production process into multiple stages. Through “standardized division of labor and refined management”, we enhance quality control, drive regulatory innovation, prioritize patients’ benefits, and improve supply chain security and drug accessibility. On June 26, 2025, our innovative ADC biological product, trastuzumab botidotin, received official approval from the NMPA to carry out the cross-provincial segmented production pilot program.
Manufacturing & Quality Platform
